Lumida
/SMTI
⌘K
Sanara Medtech Inc

Sanara Medtech Inc

SMTI
$34.92USD↓-0.31%-0.11 today

MARKET CAP

320.8M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$35 – $35

52W RANGE

$16
$36

AI Summary

Stalk
Buy NowMedium

SMTI is in a clear Stage 2 advance, trading just below its 52-week high with the 9-, 20-, 50-day, and 200-day moving averages aligned bullishly. The active Lockout Rally and Parabola patterns reflect forced repricing and steep trend acceleration, overriding typical overbought concerns. As a result, timing conditions favor immediate continuation participation (Buy Now) above the rising EMA zone. The medium-term bias remains bullish under the Momentum + EPS strategy, with primary risk centered on a sharp reversal if the 9- or 20-day EMA fails.

  • ↑Consensus FY25 EPS forecast improved from -$1.56 to -$0.98
  • ↑Agreement to acquire MiMedx expands surgical wound portfolio and synergy potential
  • ↓Negative earnings yield and low book-to-price factors signal overvaluation
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Sanara MedTech Inc. (NASDAQ: SMTI) is an emerging player in the medical technology sector, focusing on surgical wound and soft tissue products. The company operates at the innovative forefront of healthcare, developing advanced solutions aimed at addressing complex surgical challenges. As the demand for innovative healthcare solutions continues to rise, Sanara MedTech is well-positioned within the broader trend toward improved surgical outcomes and patient care.

Bull says

  • ↑Consensus FY25 EPS forecast improved from -$1.56 to -$0.98
  • ↑Agreement to acquire MiMedx expands surgical wound portfolio and synergy potential
  • ↑5 research reports in past 90 days indicate strong analyst interest
  • ↑Price target revised up to ~$34.33 on favorable revenue outlook
  • ↑Positive leverage and interest-rate sensitivity factors support growth funding
  • ↑Rising healthcare spending boosts demand for advanced wound care products

Bear says

  • ↓Negative earnings yield and low book-to-price factors signal overvaluation
  • ↓Weak profitability factors reflect inefficiencies in generating operating returns
  • ↓High short interest indicates market skepticism and downside pressure
  • ↓Negative momentum and elevated volatility deter risk-averse investors
  • ↓Consensus price targets near current levels imply limited upside
  • ↓MiMedx integration poses execution risks and may strain resources

Investment themes with SMTI

Health Care Equipment & Supplies↑ +0.40%

Clinical instruments and devices powering patient care

ABT · ISRG · SYK

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-12-2026bullish

Transcript signals

Bull points

  • This was a strong quarter for us, which exceeded our expectations. Q1 2026 was the first full quarter in which we were entirely focused on the surgical market, and the results reflect our sharpened, focused, and enhanced financial model.
  • our products were contracted or approved to be sold in over 4,000 hospitals and ambulatory surgery centers throughout the United States. Our products were sold in over 1,400 facilities throughout the United States, up from more than 1,300 in the first quarter of last year. And we had agreements with more than 450 distributors compared to 400 at this time last year.
  • our team continues to, one, get wider into facilities that they've been working in for some time, and two, reaching into new facilities as well.

Bear points

  • Other expense for the first quarter of 2026 was $2.2 million compared to $1.4 million for the first quarter of 2025. The increase in other expense was primarily due to higher interest expense and fees related to our CRG term loan and share of losses from equity method investments
Read full transcript analysis ›